Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  veliparib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 47 for your search:
Start Over
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NABTT-0801 CDR0000616542, U01CA062475, ABTC-0801, NABTT-0801, ABBOTT-M10-190, 0801, NCT00770471
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-00312, MAYO-MC0861, CDR0000657976, 09-000742, MC0861, 8329, P30CA015083, U01CA069912, NCT01012817
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-0929, CDR0000660545, NCT01026493
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02661, CDR0000693745, GOG-0076HH, U10CA027469, NCT01281852
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02583, CDR0000697580, 10-174, 8818, P30CA008748, U01CA069856, MSKCC-10174, NCT01326702
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02592, CHNMC-PHII-111, CDR0000701003, PHII-111, S1206, 8811, N01CM62209, U10CA180888, U10CA032102, NCT01386385
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-440, 2008-004941-27, NCT00804908
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-261, NCT01009788
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-170, NCT01051596
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-757, 2009-015082-31, NCT01113957
Veliparib With or Without Carboplatin in Treating Patients With Stage III or Stage IV Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01379, CHNMC-PHII-96, CDR0000674384, PHII-96, 8264, N01CM00032, N01CM00038, N01CM00039, N01CM00071, N01CM00099, N01CM62201, N01CM62202, N01CM62203, N01CM62209, P30CA033572, NCT01149083
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-273, NCT01193140
ABT-888 and Temozolomide for Liver Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-268, NCT01205828
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02659, CDR0000691281, GOG-0127W, U10CA180868, U10CA027469, GOG-0127W_2010-12-14, NCT01266447
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00684, CDR0000726699, GOG-0280, U10CA180868, U10CA027469, NCT01540565
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-897, 2011-003618-18, NCT01657799
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 12G.376, 2012-47, NCT01818063
Early Phase I Study of the Pharmacokinetics and Pharmacodynamics of ABT-888 in Patients With Refractory Solid Tumors or Lymphoid Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0172, NCI-P6890, 7675, NCT00387608
Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Patients With Advanced or Refractory Solid Tumors, Lymphoma, or Chronic Lymphocytic Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-07-C-0203, P7241, 7981, NCT00553189
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00258, PCI-07-015, CDR0000566233, UPCI # 07-015, 7967, N01CM00038, P30CA047904, U01CA099168, 07-015, NCT00535119
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M06-862, NCT00526617
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00259, CDR0000579626, J0783, 7968, P30CA006973, U01CA062491, U01CA069912, U01CA070095, JHOC-J0783, NCT00588991
Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-2009-01057, 2007-014, HIC1410014852, CDR0000579642, 7977, P30CA016359, U01CA062487, U01CA062490, UM1CA186689, WSU-2007-014, NCT00576654
Start Over